David Gauden
Chief Executive Officer Blue Earth Therapeutics Ltd.
David is Chief Executive Officer of Blue Earth Therapeutics, where he leads the company’s mission to develop innovative radiopharmaceutical therapies for cancer patients. He led the creation of the company following its spin-out from Bracco in 2021. Previously, David co-founded Blue Earth Diagnostics and served as Chief Scientific Officer and later Chief Executive Officer, helping build the company from a start-up to a leader in nuclear medicine and molecular imaging before its acquisition by Bracco Imaging in 2019. He has more than 25 years of radiopharmaceutical industry experience.
Seminars
Wednesday 2nd December 2026
Moving Beyond Fixed Dosing: Using Quantitative Dosimetry to Deliver Truly Personalised TRP Treatment
2:00 pm
- Addressing significant interpatient variability in tumour uptake, organ exposure and clearance that limits the effectiveness of one-size-fits-all dosing strategies
- Leveraging patient-specific dosimetry to optimise administered activity, retreatment schedules and cumulative dose exposure across different tumour and isotope settings
- Understanding how personalised dosimetry may improve efficacy, reduce unnecessary toxicity and support broader adoption of precision radioligand therapy approaches
